Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.

Trial Details

NCT ID
NCT04969731
Phase
PHASE3
Sponsor
GC Cell Corporation
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Immuncell-LC
  • Gemcitabine
Locations (sample)
  • Seoul, Daehak-ro, Jongno-gu, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Age \>/=20 years old, \</=80 years old.
  • Histologically or cytologically confirmed pancreatic ductal adenocarcinoma that fulfill the following requirements:
  • Participants have undergone a radical full resection (R0) or boundary resection (R1) operation and has elapsed at least two weeks after the resecti…
  • Noncancerous ascites.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →